FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasiliigtoii,	D.C.	20049

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMP Noveles	0005 0007							
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Huber Reid M				2. Issuer Name and Ticker or Trading Symbol Tango Therapeutics, Inc. [TNGX]								all applic	able) r	g Pers	son(s) to Iss	vner			
	(Fi		3. Date of Earliest Transaction (Month/Day/Year) 06/08/2022									Officer below)	(give title		Other (s below)	specify			
100 BINNEY STREET, SUITE 700					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	IDGE M	A	02142									X	•						
(City)	(S	tate)	(Zip)																
		Tab	le I - Non-I	Derivati	ive Se	ecurities	s Ac	quired, C	Disp	osed o	f, or Be	neficia	ally (Owned					
Date				2. Transacti Date Month/Day	Execution Date,			Code (Instr. 5)				4 and Securitie Beneficia		es Form ally (D) of Following (I) (II		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) or (D)		•	Transacti (Instr. 3 a	ction(s)			(111511. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)			Cod	ansaction of ode (Instr. Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and of Securitie Underlying Derivative S (Instr. 3 and			ies g Securit	De	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4	Beneficial Ownership (Instr. 4)			
				Cod	e V	(A)	(D)	Date Exercisable		xpiration ate	Title	Amour or Number of Shares	er						
Stock Option (Right to Buy)	\$5.9	06/08/2022		A		40,000		(1)	06	5/08/2032	Common Stock	40,00	0	\$0.00	40,000)	D		

Explanation of Responses:

1. This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year from June 8, 2022, subject to the Reporting Person's continuous service on the board of directors as of each such vesting date.

Remarks:

/s/ Douglas Barry, as attorneyin-fact

06/28/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.